Vanda Pharmaceuticals | VNDA - Ebitda


Vanda Pharmaceuticals reported $-8.31M in EBITDA for its fiscal quarter ending in December of 2024.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
AstraZeneca USD 5.23B 272M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -314.19M 31.48M Dec/2025
J&J USD 7.19B 2.32B Dec/2025
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
Ligand Pharmaceuticals USD 150.32M 129.42M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Moderna USD -790M 582M Dec/2025
Novartis USD 5.84B 235M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
Takeda JPY 448.13B 173.98B Dec/2025
Teva Pharmaceutical Industries USD 1.64B 243M Dec/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Veracyte USD 42.31M 2.58M Dec/2025